JP2006500388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006500388A5 JP2006500388A5 JP2004534233A JP2004534233A JP2006500388A5 JP 2006500388 A5 JP2006500388 A5 JP 2006500388A5 JP 2004534233 A JP2004534233 A JP 2004534233A JP 2004534233 A JP2004534233 A JP 2004534233A JP 2006500388 A5 JP2006500388 A5 JP 2006500388A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhibitor
- composition according
- group
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 229930003316 Vitamin D Natural products 0.000 claims 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 150000003384 small molecules Chemical class 0.000 claims 8
- 239000011710 vitamin D Substances 0.000 claims 8
- 235000019166 vitamin D Nutrition 0.000 claims 8
- 229940046008 vitamin d Drugs 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- -1 vitamin D compound Chemical class 0.000 claims 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 210000000988 bone and bone Anatomy 0.000 claims 5
- 239000011575 calcium Substances 0.000 claims 5
- 229910052791 calcium Inorganic materials 0.000 claims 5
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims 4
- 102000003945 NF-kappa B Human genes 0.000 claims 3
- 108010057466 NF-kappa B Proteins 0.000 claims 3
- 102000008108 Osteoprotegerin Human genes 0.000 claims 3
- 108010035042 Osteoprotegerin Proteins 0.000 claims 3
- 101150014014 Traf6 gene Proteins 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 239000011612 calcitriol Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- 229940121819 ATPase inhibitor Drugs 0.000 claims 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 1
- 102100034613 Annexin A2 Human genes 0.000 claims 1
- 108090000668 Annexin A2 Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229940122156 Cathepsin K inhibitor Drugs 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102100027584 Protein c-Fos Human genes 0.000 claims 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102000014128 RANK Ligand Human genes 0.000 claims 1
- 108010025832 RANK Ligand Proteins 0.000 claims 1
- 108010027767 Rank-Fc Proteins 0.000 claims 1
- 108091005682 Receptor kinases Proteins 0.000 claims 1
- 102100024817 TNF receptor-associated factor 6 Human genes 0.000 claims 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 claims 1
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 claims 1
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 102000011731 Vacuolar Proton-Translocating ATPases Human genes 0.000 claims 1
- 108010037026 Vacuolar Proton-Translocating ATPases Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims 1
- 229940062527 alendronate Drugs 0.000 claims 1
- 125000001118 alkylidene group Chemical group 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000002997 osteoclast Anatomy 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108091006084 receptor activators Proteins 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 231100000816 toxic dose Toxicity 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 238000005829 trimerization reaction Methods 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 0 CC(CCC1)(C(*)CC2)C2C1C=CC=C1C(*)(*)C(*)C(C)(*)C(CO*)C1 Chemical compound CC(CCC1)(C(*)CC2)C2C1C=CC=C1C(*)(*)C(*)C(C)(*)C(CO*)C1 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/235,244 US7259143B2 (en) | 2002-09-05 | 2002-09-05 | Method of extending the dose range of vitamin D compounds |
| PCT/US2003/020517 WO2004022068A1 (en) | 2002-09-05 | 2003-06-26 | A method of extending the dose range of vitamin d compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006500388A JP2006500388A (ja) | 2006-01-05 |
| JP2006500388A5 true JP2006500388A5 (enExample) | 2006-02-16 |
Family
ID=31977538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004534233A Pending JP2006500388A (ja) | 2002-09-05 | 2003-06-26 | ビタミンｄ化合物の投与量範囲を拡大する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7259143B2 (enExample) |
| EP (1) | EP1545549A1 (enExample) |
| JP (1) | JP2006500388A (enExample) |
| KR (1) | KR100835456B1 (enExample) |
| CN (1) | CN1694711A (enExample) |
| AU (2) | AU2003245748A1 (enExample) |
| BR (1) | BR0314006A (enExample) |
| CA (1) | CA2497828A1 (enExample) |
| MX (1) | MXPA05002467A (enExample) |
| NZ (1) | NZ539129A (enExample) |
| PL (1) | PL375558A1 (enExample) |
| WO (1) | WO2004022068A1 (enExample) |
| ZA (1) | ZA200501843B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030188756A1 (en) * | 2002-08-19 | 2003-10-09 | Cantorna Margherita T | Treatment of inflammatory bowel disease with vitamin d compounds |
| WO2003086415A1 (en) * | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| US20080249068A1 (en) * | 2002-09-05 | 2008-10-09 | Deluca Hector F | Method of Extending the Dose Range of Vitamin D Compounds |
| US7566696B2 (en) * | 2002-09-05 | 2009-07-28 | Wisconsin Alumni Research Foundation | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis |
| NZ545862A (en) * | 2003-08-20 | 2010-01-29 | Wisconsin Alumni Res Found | 2-Methylene-19-nor-vitamin D2 compounds |
| CA2539361A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist |
| WO2005027929A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen |
| US7704980B2 (en) * | 2003-10-08 | 2010-04-27 | Wisconsin Alumni Research Foundation | Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds |
| US20050261250A1 (en) * | 2004-05-19 | 2005-11-24 | Merck & Co., Inc., | Compositions and methods for inhibiting bone resorption |
| WO2006061683A1 (en) * | 2004-12-09 | 2006-06-15 | Pfizer Products Inc. | 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteogenesis imperfecta |
| US20060195353A1 (en) * | 2005-02-10 | 2006-08-31 | David Goldberg | Lead generation method and system |
| CA2597624C (en) * | 2005-02-11 | 2012-08-14 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2 |
| US7511030B2 (en) * | 2005-02-11 | 2009-03-31 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-(20S-24epi)-1α,25-dihydroxyvitamin D2 |
| JP2008530121A (ja) * | 2005-02-14 | 2008-08-07 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | 多発性硬化症を治療および予防するためのカルシトニンおよびカルシトニン様ペプチド類の使用 |
| WO2007022433A2 (en) * | 2005-08-18 | 2007-02-22 | Bioxell S.P.A. | SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL |
| US20070165866A1 (en) * | 2006-01-13 | 2007-07-19 | Motorola, Inc. | Method and apparatus to facilitate conveying audio content |
| PT2148661E (pt) * | 2007-04-25 | 2013-03-06 | Proventiv Therapeutics Llc | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso |
| US20100331286A1 (en) * | 2008-02-25 | 2010-12-30 | Ray Chow | Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function |
| TR200900878A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar |
| TR200900880A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik bileşimler. |
| AU2010300539B9 (en) * | 2009-10-02 | 2018-07-19 | Wisconsin Alumni Research Foundation | 1-desoxy-2-methylene-19-nor-vitamin D analogs and their uses |
| WO2012075326A2 (en) * | 2010-12-01 | 2012-06-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatment of inflammatory diseases by targeting the adaptor protein ciks |
| WO2013059060A1 (en) * | 2011-10-21 | 2013-04-25 | Wisconson Alumni Research Foundation | 2-methylene-vitamin d analogs and their uses |
| US9688596B2 (en) * | 2015-08-05 | 2017-06-27 | Wisconsin Alumni Research Foundation | Synthesis and biological activity of 2-methylene analogs of calcitriol and related compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6357527A (ja) | 1986-08-28 | 1988-03-12 | Toyo Jozo Co Ltd | 薬剤の吸着防止方法 |
| US5391567A (en) * | 1986-09-03 | 1995-02-21 | Macrochem Corporation | Method for treating hypercalcemia using salts of TNCA |
| US6489288B1 (en) * | 1990-03-16 | 2002-12-03 | Applied Research Systems Ars Holding | Treatment of polycystic ovarian disease |
| US5780437A (en) * | 1995-12-14 | 1998-07-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| US6271349B1 (en) * | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| US6503893B2 (en) * | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
| US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US6034075A (en) * | 1997-03-20 | 2000-03-07 | The Trustees Of Columbia University In The City Of New York | Method of treating polycystic ovarian syndrome |
| US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6087555A (en) * | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
| US6335170B1 (en) * | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| EP1267888A4 (en) | 2000-01-04 | 2005-12-28 | Univ California | USE OF LOW DOSE BISPHOSPHONATES TO INHIBIT CARDIAC AND ARTERIAL CALCIFICATION |
| IL159853A0 (en) * | 2001-07-17 | 2004-06-20 | Teva Pharma | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
-
2002
- 2002-09-05 US US10/235,244 patent/US7259143B2/en not_active Expired - Fee Related
-
2003
- 2003-06-26 MX MXPA05002467A patent/MXPA05002467A/es active IP Right Grant
- 2003-06-26 KR KR1020057003765A patent/KR100835456B1/ko not_active Expired - Fee Related
- 2003-06-26 PL PL03375558A patent/PL375558A1/xx not_active Application Discontinuation
- 2003-06-26 CN CNA038248883A patent/CN1694711A/zh active Pending
- 2003-06-26 CA CA002497828A patent/CA2497828A1/en not_active Abandoned
- 2003-06-26 NZ NZ539129A patent/NZ539129A/en not_active IP Right Cessation
- 2003-06-26 AU AU2003245748A patent/AU2003245748A1/en not_active Abandoned
- 2003-06-26 JP JP2004534233A patent/JP2006500388A/ja active Pending
- 2003-06-26 EP EP03739354A patent/EP1545549A1/en not_active Withdrawn
- 2003-06-26 WO PCT/US2003/020517 patent/WO2004022068A1/en not_active Ceased
- 2003-06-26 BR BR0314006-7A patent/BR0314006A/pt not_active IP Right Cessation
-
2005
- 2005-03-03 ZA ZA200501843A patent/ZA200501843B/en unknown
-
2009
- 2009-09-21 AU AU2009217403A patent/AU2009217403A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006500388A5 (enExample) | ||
| KR100835456B1 (ko) | 비타민 ｄ 화합물의 투여량 범위를 확장시키는 방법 | |
| KR101178318B1 (ko) | 효과적인 의약의 사용법 및 부작용 발현의 방어에 관한방법 | |
| Pozzi et al. | The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future | |
| JP2005510536A5 (enExample) | ||
| JP2010523682A5 (enExample) | ||
| US20170273952A1 (en) | Methods of treating liver disease | |
| JP2007530577A5 (enExample) | ||
| JP2009537461A5 (enExample) | ||
| JP2011506412A5 (enExample) | ||
| JP2019515884A5 (enExample) | ||
| JP2010536866A (ja) | ビタミンｄ化合物の用量範囲を拡張する方法 | |
| EP3710449B1 (en) | Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer | |
| RU2014102362A (ru) | Антитромботические соединения | |
| JP2008508279A5 (enExample) | ||
| CN113164490B (zh) | 采用p2x3拮抗剂治疗瘙痒症 | |
| US20190192527A1 (en) | Compositions comprising pikfyve inhibitors and methods related to inhibition of rank signaling | |
| WO2006123357A3 (en) | Oral controlled release composition containing levetiracetam | |
| KR102542790B1 (ko) | 브라디키닌 b1 수용체의 길항제로서의 카르복실산 방향족 아미드 | |
| JP2006523239A5 (enExample) | ||
| JP2006518756A5 (enExample) | ||
| JP2008520690A5 (enExample) | ||
| RU2331425C2 (ru) | Фармацевтические композиции и способы, включающие комбинации производных 2-алкилиден-19-нор-витамина d и агониста/антагониста эстрогенов | |
| Maehr et al. | Calcitriol derivatives with two different side chains at C-20: III. An epimeric pair of the gemini family with unprecedented antiproliferative effects on tumor cells and renin mRNA expression inhibition | |
| JP2007532540A5 (enExample) |